Comparative Pharmacology
Head-to-head clinical analysis: AMILORIDE HYDROCHLORIDE versus MIDAMOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMILORIDE HYDROCHLORIDE versus MIDAMOR.
AMILORIDE HYDROCHLORIDE vs MIDAMOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amiloride hydrochloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENaC) in the distal convoluted tubule and collecting duct of the nephron, inhibiting sodium reabsorption and reducing potassium and hydrogen ion secretion.
Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENaC) in the distal convoluted tubule and collecting duct, reducing sodium reabsorption and potassium excretion.
5-10 mg orally once daily; maximum 20 mg/day.
5 mg orally once daily, increased to 10 mg if needed; maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is 6-9 hours; prolonged to 20-24 hours in renal impairment
Terminal half-life 6-9 hours; prolonged in renal impairment (up to 20 hours) and in heart failure
Renal, approximately 50% unchanged; minor biliary/fecal elimination (<10%)
Renal: 80-90% as unchanged drug; biliary/fecal: <5%
Category C
Category C
Potassium-Sparing Diuretic
Potassium-Sparing Diuretic